Acne

Latest News


CME Content


Clinicians recognize that acne is increasingly presenting in pre-adolescents and that early presentation is also a predictor of worse disease in the future and the potential for scarring. Prompt, aggressive treatment will lead to better outcomes and will reduce the potential for adverse psychosocial effects.

The stories of the heroes behind these and other dermatologic therapeutic discoveries are recounted in the book To Heal the Skin: The Heroes Behind Discoveries in Dermatology edited by the late Stuart Maddin, M.D., F.R.C.P.C., professor emeritus at the University of British Columbia (UBC) in Vancouver, Canada, and a leader and pioneer in dermatology in Canada and internationally, and Eileen Murray, M.D., F.R.C.P.C., a dermatologist and adjunct professor at UBC. Learn more

Dermatology Times editorial advisor, Dr. Elaine Siegfried continues the discussion on isotretinoin with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania. In this final segment, the two discuss whether a waiting period is necessary before treating acne scars and the questionable existence of pityrosporum folliculitis.

New and exciting topical and oral therapeutic agents and those still in the pipeline are slated to revolutionize acne therapy, as they appear to more effectively improve the clinical symptoms of acne.

Although acne is typically regarded as an adolescent condition, acne is aleso prevalent among adults. The limited data available on the clinical characteristics and burden of acne inspires Dr. Baldwin. In this short film, Dr. Baldwin describes the universal clinical characteristics and psychosocial impact of this skin condition.

Dermatology Times editorial advisor, Dr. Elaine Siegfried continues the discussion on isotretinoin with James Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania. Here, the two discuss isotretinoin dosing and side effects.

Conventional acne treatment guidelines focus on acne severity. But there’s much more to effectively treating individual acne patients, according to an expert panel of 13 Canadian dermatologists, who developed a case-centered multifactorial consensus on acne management. Learn more

Dermatology Times editorial advisor Dr. Elaine Siegfried talks with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania about the art and science of isotretinoin therapy. Dr. Leyden, aside from being a member of the famed Acne Mafia, was a really active participant in the drug development process for isotretinoin, a drug for which, the institutional memory about that process may be fading. The two discuss many of the important initial clinical observations and those that others have made over the years.